An interventional study of Home-based multimodal cardiovascular screening in Cardiovascular Diseases, Hypertension and Dyslipidemias, sponsored by Johan Sundström. Recruiting at 1 site in Sweden. Open to participants aged 50 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Johan Sundström · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
U-SCREEN is a randomized controlled trial evaluating whether systematic home-based multimodal screening for cardiovascular risk conditions, offered to residents in Region Uppsala turning 50, 55, 60, 65, 70 or 75 years of age, can identify clinically actionable cardiovascular risk factors more effectively than usual care. Participants randomized to the screening arm receive a home blood pressure measurement device, a dried blood spot sampling kit (for ApoB, HbA1c and creatinine), and a digital questionnaire. The control arm receives usual care. Recruitment runs 2024-2027 with a target identification of 10,000 cardiovascular risk conditions.
BACKGROUND Cardiovascular disease remains the leading cause of death and disability in Sweden and globally. Hypertension, dyslipidemia, diabetes, atrial fibrillation, and chronic kidney disease are largely asymptomatic but treatable conditions for which effective preventive interventions exist. Despite this, a substantial proportion of affected individuals are undiagnosed or untreated. Population-based screening at clinics is resource-intensive and reaches only a fraction of those at risk. Digital tools and home-based self-sampling now make it feasible to scale cardiovascular screening to whole populations at limited marginal cost.
OBJECTIVES To determine whether a home-based multimodal cardiovascular screening program identifies more cardiovascular risk conditions than usual care in middle-aged and older adults. To evaluate the impact of screening on initiation of evidence-based preventive treatment; on cardiovascular events; on healthcare utilization and costs; and on participant-reported outcomes including health-related quality of life.
DESIGN Pragmatic, register-based, two-arm parallel-group randomized controlled trial. Eligible residents in Region Uppsala turning 50, 55, 60, 65, 70 or 75 years during the recruitment period are invited and, after digital informed consent, randomized 1:1 to the screening arm or the control arm.
INTERVENTION (SCREENING ARM)
Participants receive a home package containing:
Results are returned to the participant via a digital portal together with structured advice; participants with findings exceeding pre-specified thresholds receive guideline-directed pharmacotherapy and are referred for clinical follow-up in routine care.
COMPARATOR (CONTROL ARM) Usual care, with no active screening offered as part of the trial.
OUTCOME ASCERTAINMENT Outcomes are ascertained primarily through linkage to Swedish national health registers (the National Patient Register, the Swedish Prescribed Drug Register, the Cause of Death Register, and quality registers including SWEDEHEART and the Swedish Primary Care Cardiovascular Database) and to regional electronic health records.
SAMPLE SIZE AND ANALYSIS The trial targets identification of 10,000 cardiovascular risk conditions. Analyses follow the intention-to-treat principle.
5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.
This study's planned enrollment of 45,000 is above the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →This is the only study on the registry with Johan Sundström as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Home cardiovascular screening package: 7-day home BP measurement; dried blood spot self-sampling for ApoB, HbA1c and creatinine; digital questionnaire on lifestyle, symptoms, family history, diagnoses, medications. Above-threshold findings trigger initiation of guideline-recommended pharmacotherapy and referral to clinical care.
Behavioral: Home-based multimodal cardiovascular screening
Usual care. No active screening offered as part of trial. Outcomes via national register and EHR linkage.
Self-administered home-based screening program: 7-day home BP, DBS biomarker self-sampling, digital questionnaire; structured digital return of results; threshold-based initiation of guideline-recommended pharmacotherapy and referral to clinical care.
Rate of total major adverse cardiovascular events over 10 years
Time frame: Within 10 years after randomization
Number of initiated guideline-recommended pharmacotherapies for cardiovascular risk factors within 12 months
Time frame: Within 12 months after randomization
All-cause mortality
Time frame: Within 10 years after randomization.
Rate of cardiovascular deaths
Time frame: Within 10 years after randomization.
Rate of total hospitalizations and deaths
Time frame: Within 10 years after randomization.
Rate of cardiovascular hospitalizations and deaths from ischaemic heart disease
Time frame: Within 10 years after randomization.
Rate of cardiovascular hospitalizations and deaths from cerebrovascular heart disease
Time frame: Within 10 years after randomization.
Plan to share: Undecided — Decisions on sharing of de-identified IPD will follow Swedish and EU data protection legislation and sponsor/Uppsala University policies. Aggregate results will be published in peer-reviewed journals.
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.
Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 34 months is above that.
Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.